KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Investment Income (2019 - 2025)

Royalty Pharma's Non Operating Investment Income history spans 7 years, with the latest figure at -$1.0 million for Q4 2025.

  • For Q4 2025, Non Operating Investment Income rose 88.89% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$8.0 million, down 366.67%, while the annual FY2024 figure was -$6.0 million, 162.01% down from the prior year.
  • Non Operating Investment Income for Q4 2025 was -$1.0 million at Royalty Pharma, down from $4.0 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $71.8 million in Q2 2022 and bottomed at -$17.0 million in Q3 2021.
  • The 5-year median for Non Operating Investment Income is -$990000.0 (2022), against an average of $4.2 million.
  • The largest YoY upside for Non Operating Investment Income was 3861.39% in 2022 against a maximum downside of 920.83% in 2022.
  • A 5-year view of Non Operating Investment Income shows it stood at -$96000.0 in 2021, then tumbled by 920.83% to -$980000.0 in 2022, then plummeted by 785.71% to -$8.7 million in 2023, then dropped by 3.69% to -$9.0 million in 2024, then surged by 88.89% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Non Operating Investment Income are -$1.0 million (Q4 2025), $4.0 million (Q3 2025), and -$2.0 million (Q2 2025).